Page 12 - அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The study demonstrated that this biomarker, a molecule called the Major Histocompatibility Complex Class II protein (MHC-II), has the potential to be a predictor of immunotherapy benefit with two types of breast cancer early-stage, triple negative breast cancer (TNBC) and high-risk, estrogen receptor-positive breast cancer (HR+) when expressed on breast cancer cells. Although immunotherapies are likely to soon be prescribed along with chemotherapies for these breast cancers before surgery, most patients don t require the addition of immunotherapy to achieve treatment response. Without an optimal biomarker, clinicians don

United statesPaula gonzalez ericssonKim blenmanJustin balkoEmily hendersonAmerican association for cancer researchMedicine at yale universityClinical cancer researchAmerican associationMajor histocompatibility complex classGonzalez ericssonஒன்றுபட்டது மாநிலங்களில்ஜஸ்டின் பால்கோஎமிலி ஹென்டர்சன்அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சிமருந்து இல் யேல் பல்கலைக்கழகம்